Fasiha Kanwal, Jennifer R. Kramer, Steven M. Asch, Yumei Cao, Liang Li, Hashem B. El‐Serag – 20 June 2019 – Sustained virologic response (SVR) after direct acting antiviral agents (DAAs) holds promise for reducing hepatocellular cancer (HCC). DAAs have recently been available long enough to estimate the long‐term risk. We conducted a retrospective cohort study of hepatitis C virus (HCV) patients who achieved SVR with DAAs from 129 Veterans Health Administration hospitals between January 1, 2015, and December 31, 2015, with follow‐up through September 30, 2018.

Philip Rosenthal, Kathleen B. Schwarz, Regino P. Gonzalez‐Peralta, Chuan‐Hao Lin, Deidre A. Kelly, Scott Nightingale, William F. Balistreri, Sanjay Bansal, Maureen M. Jonas, Benedetta Massetto, Diana M. Brainard, Chia‐Hsiang Hsueh, Jiang Shao, Bandita Parhy, Suzanne Davison, Cornelia Feiterna‐Sperling, Lynette A. Gillis, Giuseppe Indolfi, Etienne M. Sokal, Karen F. Murray, Stefan Wirth – 20 June 2019 – Currently, the only approved hepatitis C virus (HCV) treatment for children aged <12 years is pegylated interferon plus ribavirin.

Yutao Wang, Huan Wen, Jiajun Fu, Lin Cai, Peng‐Long Li, Chang‐Ling Zhao, Zhu‐feng Dong, Jun‐peng Ma, Xi Wang, Han Tian, Yan Zhang, Ye Liu, Jingjing Cai, Zhi‐Gang She, Zan Huang, Wenhua Li, Hongliang Li – 20 June 2019 – Activation of apoptosis signal‐regulating kinase 1 (ASK1) is a key driving force of the progression of nonalcoholic steatohepatitis (NASH) and represents an attractive therapeutic target for NASH treatment. However, the molecular and cellular mechanisms underlying ASK1 activation in the pathogenesis of NASH remain incompletely understood.

20 June 2019

Thomas Horvatits, Andreas Drolz, Michael Trauner, Valentin Fuhrmann – 19 June 2019 – The frequency of acquired liver injury and failure in critical illness has been significantly increasing over recent decades. Currently, liver injury and failure are observed in up to 20% of patients in intensive care units and are associated with significantly increased morbidity and mortality. Secondary forms of liver injury in critical illness are divided primarily into cholestatic, hypoxic, or mixed forms.

Manali Dimri, Ashley Humphries, Archana Laknaur, Sawsan Elattar, Tae Jin Lee, Ashok Sharma, Ravindra Kolhe, Ande Satyanarayana – 19 June 2019 – Cancer cells undergo metabolic adaptation to sustain uncontrolled proliferation. Aerobic glycolysis and glutaminolysis are two of the most essential characteristics of cancer metabolic reprogramming.

Menghao Huang, Hyeong Geug Kim, Xiaolin Zhong, Chuanpeng Dong, Brian Zhang, Zhigang Fang, Yang Zhang, Xiaoyu Lu, Romil Saxena, Yunlong Liu, Chi Zhang, Suthat Liangpunsakul, X. Charlie Dong – 19 June 2019 – Sestrin 3 (Sesn3) belongs to the three‐member sestrin protein family. Sestrins have been implicated in antioxidative stress, adenosine monophosphate–activated protein kinase and mammalian target of rapamycin signal transduction, and metabolic homeostasis. However, the role of Sesn3 in the development of nonalcoholic steatohepatitis (NASH) has not been previously studied.

Vincent L. Chen, Andrew P. Wright, Brian Halligan, Yanhua Chen, Xiaomeng Du, Samuel K. Handelman, Michelle T. Long, Douglas P. Kiel, Elizabeth K. Speliotes – 18 June 2019 – Up to 25% of patients with nonalcoholic fatty liver disease (NAFLD) are not obese but may have a fat or muscle composition that predisposes them to NAFLD. Our aim was to determine whether body composition parameters associate with NAFLD and to identify genetic contributors to this association. This study included two cohorts.

Anna Baiges, Fanny Turon, Macarena Simón‐Talero, Stephanie Tasayco, Javier Bueno, Kamal Zekrini, Aurélie Plessier, Stéphanie Franchi‐Abella, Florent Guerin, Amar Mukund, C.E.

Colm J. O’Rourke, Matthias S. Matter, Chirag Nepal, Rui Caetano‐Oliveira, Phuongnga T. Ton, Valentina M. Factor, Jesper B. Andersen – 18 June 2019 – Cholangiocarcinoma (CCA) mortality rates are increasing as a result of rising incidence and limited curative treatment(s) for patients with advanced disease. NOTCH pathway reactivation has been reported in biliary malignancies to conflicting degrees, hindering prioritization of key therapeutic targets within the network and identification of candidate responder patients for NOTCH‐directed therapies.